Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome

Inclusion Criteria: * Sign the informed consent form * Capability of independent living (capability of dressing, bathing, walking, and bed-chair transfer) * Met Motoric Cognitive Risk Syndrome (MCR) criteria: Single task slow gait ( male 60 to 74 y, gait \<75.4 cm/s; male ≥ 75 y, gait \< 59.1 cm/s; female 60 to 74 y, gait \<70.0 cm/s; female ≥ 75 y, gait \< 48.3 cm/s) And The Montreal Cognitive Assessment (MoCA) ≤ 26 (≥ 12 education year) or MoCA ≤ 25 (\< 12 education year) * Anticipated good compliance per protocol Exclusion Criteria: * Illiteracy * The Mini-Mental State Examination (MMSE) ≤ 23 * Medical history of mental illness such as schizophrenia, severe anxiety and depression. * Medical history of Alzheimer's disease, Parkinson's disease, frontotemporal dementia or Huntington's disease. * Dementia caused by other causes (such as central nervous system trauma, tumor, infection, metabolic disease, normal pressure hydrocephalus, folic acid, vitamin B12 deficiency, thyroid Inferior functions, etc.). * History of epilepsy, or taking anti-epileptic drugs. * History of myocardial infarction or stroke * History of malignant tumor * Coagulation disorder, systemic bleeding; or previous coagulation disorder or systemic bleeding disease history. * History of thrombocytopenia or neutropenia. * History of blood system diseases or liver function abnormalities caused by medication * Contraindications to ginkgo drugs and a history of known allergies. * Aphasia, severe hearing or v…